BioWorld

Oct. 8, 2007

MAP's IPO Prices Lower Than Expected But Still Raises $60M

MAP Pharmaceuticals Inc. is adding $60 million through an initial public offering to support an upcoming Phase III trial of its late-stage aerosolized products for asthma and migraine. (BioWorld Today) Read More

Haptogen Acquisition Brings Shark Therapies To Wyeth

Academia May Be Suffering But Biotech Chugs Along

Targeting Cellular MicroRNA Can Flush HIV Out Of Hiding

Pfizer Launches Bay Area Biotech Innovation Center

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for April 1, 2026.

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026

Amlogenyx’s AM-805 reduces amyloid plaques in AD

BioWorld Science

The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...